Arena continue to meet the Merck

Published: 12-Aug-2004

Arena Pharmaceuticals, of San Diego, CA, has received a $3m milestone payment from Merck & Co for assay development under their cardiovascular collaboration.


Arena Pharmaceuticals, of San Diego, CA, has received a $3m milestone payment from Merck & Co for assay development under their cardiovascular collaboration.

In October 2002, Arena and Merck entered into a collaboration focused on a group of GPCR targets discovered by Arena, which may represent novel targets for cardiovascular disease. Arena announced in the first quarter of 2004 the achievement of a $4m milestone under this collaboration related to animal testing of small molecules in this program.

'We are pleased with Merck's commitment to the cardiovascular program and their further validation of our GPCR research programs,' commented Dr Dominic Behan, Arena's co-founder, senior vice president and cso. 'We look forward to continuing our work with Merck to achieve our mutual goal of developing a successful product to treat cardiovascular disease.'

You may also like